Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10253494 | 0.86 | NOTUM (0.44) | AKT1 | |
| SCHEMBL1998171 | 0.83 | GABRD (0.35) | KCNH2PROKR1AKT1TACR3GFER | |
| SCHEMBL1689732 | 0.81 | NOTUM (0.51) | PROKR1AKT1TACR3 | |
| Trifluoroacetic Acid SCHEMBL1689684 | 0.80 | HDAC1 (0.42) | AKT1 | |
| SCHEMBL19444822 | 0.79 | GABRD (0.39) | PROKR1TACR3GFERGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL2351254 | 0.78 | AKT1 (0.42) | PROKR1AKT1 | |
| SCHEMBL29640159 | 0.78 | KCNH2 (0.52) | KCNH2AKT1 | |
| SCHEMBL1997435 | 0.76 | PROKR1 (0.40) | KCNH2PROKR1TACR3GFER | |
| SCHEMBL14675951 | 0.74 | PDE4B (0.36) | PROKR1AKT1 | |
| SCHEMBL6002678 | 0.73 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960401-B2 | Spiropiperidine derivatives for controlling pests | SYNGENTA CROP PROTECTION, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1694677-B1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20070135408-A1 | Spiropiperidine derivatives for controlling pests | SYNGENTA CROP PROTECTION, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135408-A1 | Spiropiperidine derivatives for controlling pests | CHRM1, CHRM2, RER1 | KCNH2 348/4885PROKR1 1330/4885CRBN 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.